12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zaltrap ziv-aflibercept regulatory update

The European Commission approved Zaltrap aflibercept from Sanofi in combination with FOLFIRI chemotherapy to treat metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. Sanofi, which is...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >